Neurotech International Ltd (NTI) - Total Liabilities
Based on the latest financial reports, Neurotech International Ltd (NTI) has total liabilities worth AU$932.85K AUD (≈ $660.05K USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Neurotech International Ltd - Total Liabilities Trend (2015–2025)
This chart illustrates how Neurotech International Ltd's total liabilities have evolved over time, based on quarterly financial data. See Neurotech International Ltd (NTI) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Neurotech International Ltd Competitors by Total Liabilities
The table below lists competitors of Neurotech International Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Altamin Ltd
AU:AZI
|
Australia | AU$1.03 Million |
|
Highway 50 Gold Corp
V:HWY
|
Canada | CA$742.98K |
|
Golden Land Bhd
KLSE:7382
|
Malaysia | RM208.49 Million |
|
Quantum BioPharma Ltd.
NASDAQ:QNTM
|
USA | $6.65 Million |
|
Inter-M Corporation
KQ:017250
|
Korea | ₩49.66 Billion |
|
Polyrizon Ltd. Ordinary Shares
NASDAQ:PLRZ
|
USA | $364.00K |
|
Les Hôtels de Paris SA
PA:HDP
|
France | €236.82 Million |
|
Peak Processing Limited
AU:PKP
|
Australia | AU$18.75 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Neurotech International Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see NTI company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 7.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Neurotech International Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Neurotech International Ltd (2015–2025)
The table below shows the annual total liabilities of Neurotech International Ltd from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-06-30 | AU$285.74K ≈ $202.18K |
-9.20% |
| 2024-06-30 | AU$314.70K ≈ $222.67K |
-76.63% |
| 2023-06-30 | AU$1.35 Million ≈ $952.99K |
+127.14% |
| 2022-06-30 | AU$592.98K ≈ $419.57K |
-48.19% |
| 2021-06-30 | AU$1.14 Million ≈ $809.75K |
+57.40% |
| 2020-06-30 | AU$727.10K ≈ $514.47K |
+104.62% |
| 2019-06-30 | AU$355.33K ≈ $251.42K |
-5.41% |
| 2018-06-30 | AU$375.66K ≈ $265.80K |
-42.83% |
| 2017-06-30 | AU$657.04K ≈ $464.90K |
-26.43% |
| 2016-06-30 | AU$893.12K ≈ $631.94K |
-55.08% |
| 2015-12-31 | AU$1.99 Million ≈ $1.41 Million |
-- |
About Neurotech International Ltd
Neurotech International Limited, a clinical-stage biopharmaceutical development company, engages in the research, design, development, and manufacture of medical devices and solutions in Australia. The company focuses on development and commercialization of NTI164 for multiple paediatric neurological disorders; and Mente, a clinically proven home therapy aimed at enhancing engagement and relaxati… Read more